Safety of rosuvastatin

Pasternak, 2002, ACC/AHA/NHLBI clinical advisory on the use and safety of statins, J Am Coll Cardiol, 40, 567, 10.1016/S0735-1097(02)02030-2 Staffa, 2002, Cerivastatin and reports of fatal rhabdomyolysis, N Engl J Med, 346, 539, 10.1056/NEJM200202143460721 Beaumont, 1970, Classification of hyperlipidaemia and hyperlipoproteinaemias, Bull World Health Organ, 43, 891 Illingworth, 2001, A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial, Curr Med Res Opin, 17, 43, 10.1185/0300799039117026 Insull, 2000, Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial, J Int Med Res, 28, 47, 10.1177/147323000002800201 1993 Olsson, 2002, Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia, Am Heart J, 144, 1044, 10.1067/mhj.2002.128049 Myers, 1989, The Centers for Disease Control–National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements, Clin Lab Med, 9, 105, 10.1016/S0272-2712(18)30645-0 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Fodili, 2003, Severe rhabdomyolysis and acute renal failure following recent coxsackie B virus infection, Neth J Med, 61, 177 Vidt, 2004, Rosuvastatin-induced arrest in progression of renal disease, Cardiology, 102, 52, 10.1159/000077704 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 De Backer, 2003, European guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6 Knopp, 1999, Drug treatment of lipid disorders, N Engl J Med, 341, 498, 10.1056/NEJM199908123410707 Black, 1998, An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor, Arch Intern Med, 158, 577, 10.1001/archinte.158.6.577 Newman, 2003, Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients, Am J Cardiol, 92, 670, 10.1016/S0002-9149(03)00820-8 Farmer, 2000, Comparative tolerability of the HMG-CoA reductase inhibitors, Drug Saf, 23, 197, 10.2165/00002018-200023030-00003 Davidson, 2001, Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust, Drugs, 61, 197, 10.2165/00003495-200161020-00005 Black, 2002, A general assessment of the safety of HMG CoA reductase inhibitors (statins), Curr Atheroscler Rep, 4, 34, 10.1007/s11883-002-0060-0 Bakker-Arkema, 2000, Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels, Atherosclerosis, 149, 123, 10.1016/S0021-9150(99)00294-4 Thompson, 2003, Statin-associated myopathy, JAMA, 289, 1681, 10.1001/jama.289.13.1681 Jones, 2003, Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ. Inhibitors of HMG-CoA reductase reduce receptormediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004; in press. Verhulst A, D'haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 2004; in press. McKenney, 2003, Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial, Curr Med Res Opin, 19, 689, 10.1185/030079903125002405 Olsson, 2003, Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor, Cardiovasc Drug Rev, 20, 303, 10.1111/j.1527-3466.2002.tb00099.x Schuster, 2003, Rosuvastatin—a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10–40 mg doses in dyslipidemic patients, Cardiology, 99, 126, 10.1159/000070669